Table 3. Univariate analysis of L-asp-related hyperglycemia.

		During entire treatment			Induction phase			Maintenance phase
		Odds ratio	95% CI	p-value	Odds ratio	95% CI	p-value	Odds ratio	95% CI	p-value
Age at onset (yrs)
	1–4 vs 5–18	1.000			1.000			1.000
		4.534	2.441–8.422	<0.0001	1.330	1.330–3.500	0.564	11.157	3.323–37.462	<0.0001
	1–9 vs 10–18	1.000			1.000			1.000
		5.442	3.308–8.953	<0.0001	3.731	1.424–9.778	0.0074	7.299	3.882–15.247	<0.0001
	1–14 vs 15–18	1.000			1.000			1.000
		3.656	1.455–9.183	0.006	7.629	2.082–27.954	0.002	1.685	0.493–5.759	0.405
Sex
	female	1.000			1.000			1.000
	male	0.824	0.506–1.340	0.4342	1.158	0.432–3.453	0.7065	0.519	0.281–0.957	0.0358
Risk
	SR	1.000			1.000			-	-	-
	HR	3.670	1.761–7.646	0.0005	0.628	0.217–2.630	0.6601	1.000
	ER	4.735	1.974–11.361	0.0005	2.043	0.434–7.825	0.4069	1.001	0.449–2.234	0.9981
	F	1.148	0.243–5.421	0.8620	-	-	-	-	-	-
	T	2.264	0.679–7.547	0.1833	1.667	0.330–8.415	0.5363	0.286	0.067–1.216	0.0902
BMI
	< 22%	1.000			1.000			1.000
	≥ 22%	4.713	2.064–10.761	0.0002	6.636	1.822–24.177	0.0041	6.716	2.385–18.913	0.0003
BMI percentile
	< 85%	1.000			1.000			1.000
	≥ 85%	2.042	1.147–3.637	0.0153	2.414	0.839–6.945	0.1021	1.931	0.953–3.911	0.0677
Obesity index
	< 20%	1.000			1.000			1.000
	≥20%	2.908	1.413–5.984	0.0037	3.315	0.930–11.823	0.0647	2.805	1.160–6.783	0.0221
Down syndrome
	Absent	1.000			1.000			1.000
	Present	3.286	1.086–9.946	0.0352	2.975	0.378–23.430	0.3005	3.853	0.755–19.671	0.1049

BMI, body mass index; CI, Confidence interval; ER, extremely high risk; F, induction failure; HR, high risk; SD, standard deviation; SR, standard risk; T, T-cell type.